News

Almirall and Absci Join Forces to Innovate in Dermatology with AI

Almirall and Absci Join Forces to Innovate in Dermatology with AI

AI-Driven Innovations in Dermatology: Almirall and Absci Collaboration

In a significant advancement within the pharmaceutical landscape, Almirall, a prominent biopharmaceutical company, has recently expanded its collaboration with Absci Corporation. This partnership focuses on the innovative use of artificial intelligence (AI) in drug discovery, particularly for dermatological applications. With the selection of a second target in their AI Drug Creation collaboration, both companies are positioning themselves at the forefront of therapeutic advancements.

Forging New Paths in Drug Discovery

The announcement follows a successful initial collaboration that saw the design of AI-generated antibody leads targeting challenging disease conditions. By combining Almirall’s rich expertise in dermatology with Absci’s cutting-edge Integrated Drug Creation™ platform, this partnership aims to develop breakthrough therapeutic options for patients suffering from chronic skin diseases.

AI in Action: Effective Therapeutic Designs

Prior achievements in the collaboration showcase how Absci's de novo AI design capabilities can create functional antibodies where traditional approaches have struggled. Dr. Karl Ziegelbauer, Chief Scientific Officer at Almirall, emphasized the potential of AI in revolutionizing the development of therapeutics: “Using advanced AI capabilities to design therapeutic candidates against historically challenging disease targets is a highly promising approach.” This sentiment highlights the shared vision that both companies maintain towards innovating treatment options for dermatological conditions.

Harnessing Technology for Better Treatments

Under the terms of their collaboration, Absci will leverage its generative AI platform alongside its wet lab capabilities. This collaboration enables the design and validation of therapeutic candidates, while Almirall takes the lead in advancing these candidates through preclinical and clinical development stages. This synergy not only accelerates the pace of innovation but also enhances the likelihood of successful drug development.

Future Opportunities and Financial Incentives

As part of this expanded partnership, Absci could potentially receive up to $650 million in various payments, including upfront investments, research and development contributions, and post-approval milestone payments. Additionally, royalties on future product sales will further incentivize Absci’s commitment to the project.

A Vision for the Future of Dermatology

Sean McClain, CEO of Absci, expressed optimism about the collaboration's future: “The progress in our collaboration is a testament that AI de novo drug design is a successful approach to unlock novel biology where traditional drug discovery approaches have failed.” This positive outlook indicates a deepening relationship between the two companies aimed at revolutionizing the field of dermatology through innovative AI-generated therapeutics.

About Almirall and Absci

Almirall, established in 1944 and based in Barcelona, has a longstanding dedication to advancing medical dermatology. The company collaborates extensively with healthcare professionals, scientists, and patients to enhance therapeutic outcomes, emphasizing their mission to improve the overall patient experience.

On the other hand, Absci focuses on reshaping drug discovery processes through its Integrated Drug Creation™ platform. By utilizing advanced AI alongside traditional synthetic biology methods, Absci aims to create biologics that effectively address difficult therapeutic targets. This alignment of expertise positions both companies as key players in the evolution of healthcare.

Frequently Asked Questions

What is the focus of the Almirall and Absci collaboration?

The collaboration focuses on leveraging AI in drug discovery specifically targeting dermatological conditions.

What technology does Absci use in its drug discovery process?

Absci utilizes its Integrated Drug Creation™ platform, which combines generative AI with synthetic biology to develop innovative therapeutics.

What financial incentives does Absci receive from the collaboration?

Absci can potentially receive up to $650 million in various payments, plus royalties on product sales.

Why is AI significant in drug discovery for dermatology?

AI aids in designing effective therapeutic candidates, especially for challenging disease targets that traditional methods struggle with.

How long has Almirall been in operation?

Almirall was founded in 1944, making it a well-established entity in the biopharmaceutical landscape with extensive experience in dermatology.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 110

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
VisionX AI Bets on Graphs to Track Crypto Crime Nets

Updated Category News Views 36

Money laundering rarely travels in a straight line, and that is precisely the sore spot VisionX AI is trying to jab. The Singapore-based RegTech company has introduced AEGIS, a proprietary Large Graph Model built around financial-crime networks, alongside TraceX, a blockchain investigation platform meant to turn that network view into usable leads. It is a sensible...

Continue Reading
CJ BIO Bets on Better Taste for Cleaner Food Labels

Updated Category News Views 12

A bland reduced-salt sauce can wreck months of product development in one spoonful. That unglamorous reality sits underneath CJ BIO's November 17-19 appearance at Fi Europe 2026 in Frankfurt, where the company is pitching food makers on a simple but stubborn proposition: healthier-looking labels cannot come at the expense of taste. Flavor Is Still the Gatekeeper CJ BIO is...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 183

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 72

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 97

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
MacDill Mold Case Puts Privatized Housing on Notice

Updated Category News Views 68

Four hundred fifty-four people are a hard number to shrug off. The expanded civil case over alleged toxic mold conditions at MacDill Air Force Base now covers 105 military families, up from 39 households when it was filed in September 2025. Their complaint against The Michaels Organization and affiliated entities may be the largest known military-housing lawsuit in the...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 148

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 118

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
Suntory Flowers Tests NASCAR as a Garden Retail Engine

Updated Category News Views 73

Orange sheet metal and flowering vines are an odd couple, which is precisely why this South Florida promotion has some bite. A plant marketer took a hard left turn Suntory Flowers put its Sun Parasol mandevillas alongside DGM Racing at Homestead-Miami Speedway, celebrating the millions of plants grown in South Florida. That is not a conventional horticulture play, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Cooling Garment Enhances Comfort and Safety

Updated Category News Views 195

Innovative Cooling Garment Enhances Comfort and Safety An inventive idea emerges from Pittsburgh, where a passionate creator from Yonkers has designed a unique garment to provide comfort during hot weather. This innovative attire, aptly named the GAIT, offers a cooling effect that surrounds wearers, ensuring they stay safe and comfortable no matter the temperature. The...

Continue Reading
Discovering Next-Gen Oncology Treatments at the ASH Meeting

Updated Category News Views 229

Innovative Presentations from Nurix Therapeutics NURIX Therapeutics, Inc. (NASDAQ: NRIX), a pioneering biopharmaceutical company dedicated to transforming cancer treatment, is set to showcase its significant advancements at a renowned medical meeting. Updated clinical data from the NX-5948-301 Phase 1a/1b trial has been selected for presentation at the 67th American...

Continue Reading
OU Health Partners with Razom to Transform Surgical Training

Updated Category News Views 264

OU Health and Razom Enhance Humanitarian Surgical Training In an inspiring collaboration, OU Health has recently welcomed a significant cohort of Ukrainian surgeons into its humanitarian training program, marking an important milestone in providing essential surgical training for those addressing complex trauma injuries. Expanding the Program The program, which has just...

Continue Reading
Investors Urged to Act: Lead the Charge Against Sarepta

Updated Category News Views 150

Investors May Have A Path Forward Against Sarepta Therapeutics For those who invested in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and have faced significant losses, recent developments present an opportunity to take action. There exists a growing concern regarding the safety implications of one of the company’s leading products, raising questions about transparency and...

Continue Reading
Lindian's Bold Leap into Rare Earths Processing

Updated Category News Views 58

Changing the Game in Rare Earths When Lindian Resources announces a partnership, it's not just window dressing. This time, they've linked arms with Carester SAS for a hefty venture into oxide separation. The scope? An 8,000-tonne REO facility in Kazakhstan, a place already stamped as a geological treasure chest. We're staring at what could potentially be a new dawn for...

Continue Reading